Inhaled drugs firm plans flotation

A biotechnology company which is developing an inhaled alternative to Viagra today announced plans to float on the London stock market.

Vectura, is hoping to raise between £20m (€30m) and £25m 9€37.6m) through the placing to give the company a market value of up to £85 million.